Recent Quotes (30 days)

You have no recent quotes
chg | %

Accelerate Diagnostics Inc  

(Public, NASDAQ:AXDX)   Watch this stock  
Find more results for AXDX
27.25
+0.55 (2.06%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 26.25 - 27.45
52 week 16.75 - 30.45
Open 26.30
Vol / Avg. 410,095.00/710,622.00
Mkt cap 1.54B
P/E     -
Div/yield     -
EPS -1.20
Shares 55.40M
Beta 2.16
Inst. own 49%
Nov 28, 2017
Accelerate Diagnostics Inc at Piper Jaffray Healthcare Conference
Nov 2, 2017
Q3 2017 Accelerate Diagnostics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -2062.20% -26981.30%
Operating margin -2091.18% -27032.93%
EBITD margin - -26077.24%
Return on average assets -48.17% -59.75%
Return on average equity -50.37% -62.96%
Employees 193 -
CDP Score - -

Address

3950 S. Country Club Road #470 Building 3-307
TUCSON, AZ 85714-2240
United States - Map
+1-303-8638088 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

Officers and directors

John Patience Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Lawrence Mehren President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Steve Reichling Chief Financial Officer
Age: 38
Bio & Compensation  - Reuters
Joan Martin Executive Vice President & Head of Europe, Middle East, and Africa
Age: 48
Bio & Compensation  - Reuters
Ron Price Senior Vice President and Head of Commercial Operations, Americas
Age: 53
Bio & Compensation  - Reuters
Charles Watts Director
Bio & Compensation  - Reuters
Tom Brown Independent Director
Age: 68
Bio & Compensation  - Reuters
Mark C. Miller Independent Director
Age: 61
Bio & Compensation  - Reuters
Jack W. Schuler Independent Director
Age: 76
Bio & Compensation  - Reuters
Matthew W. Strobeck Ph.D. Independent Director
Age: 44
Bio & Compensation  - Reuters